7-Azaindenoisoquinolines as Anticancer Agents
- Summary
- Researchers at Purdue University have developed a series of 7-azaindenoisoquinoline derivatives that act to inhibit topoisomerase and subsequently induce cell death. This new class of topoisomerase inhibitors has the potential to possess enhanced chemical stability over traditional inhibitors, while increasing inhibitor effectiveness.
- Technology Benefits
- Azaindenoisoquinolines have enhanced chemical stability and effectiveness over other TOP1 inhibitorsTOP1 is a proven target for cancer therapy
- Technology Application
- Cancer TreatmentMedical/HealthcarePharmaceuticals
- Detailed Technology Description
- Mark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Countries
- United States
- Application No.
- 8,686,146
- *Abstract
-
- *Background
- Topoisomerase 1 (TOP1) is an important protein found in the cell; it is used to unwind and reduce torsional stress on DNA during replication. TOP1 inhibitors are a useful chemotherapy agent because cells that are constantly dividing, such as cancer cells, are much more susceptible to attack; cell death will occur when topoisomerase 1 is inhibited. TOP1 inhibitors make up a large portion of the chemotherapy market because they can be used to target a wide variety of proliferating tumors. The characteristic of uninhibited division is a common feature in cancer that can be targeted without needing a specific marker for each cancer cell type. As more information becomes readily available, it is becoming apparent that within tumors there is a heterogeneous population of cells populating the primary tumor and the secondary tumors.
- *IP Issue Date
- Apr 1, 2014
- *IP Type
- Utility
- *Stage of Development
- Proof of Concept
- *Web Links
- Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipMark CushmanPurdue Medicinal Chemistry and Molecular Pharmacology
- Country/Region
- USA
For more information, please click Here
